Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC
Janssen Research & Development, LLC
Byoung C Cho; Shun Lu; Enriqueta Felip; Alexander I Spira; Nicolas Girard; Jong-Seok Lee; Se-Hoon Lee; Yurii Ostapenko; Pongwut Danchaivijitr; Baogang Liu; Adlinda Alip; Ernesto Korbenfeld; Josiane Mourão Dias; Benjamin Besse; Ki-Hyeong Lee; Hailin Xiong; Soon-Hin How; Ying Cheng; Gee-Chen Chang; Hiroshige Yoshioka; James C-H Yang; Michael Thomas; Danny Nguyen; Sai-Hong I Ou; Sanjay Mukhedkar; Kumar Prabhash; Manolo D'Arcangelo; Jorge Alatorre-Alexander; Juan C Vázquez Limón; Sara Alves; Daniil Stroyakovskiy; Marina Peregudova; Mehmet A N Şendur; Ozan Yazici; Raffaele Califano; Vanesa Gutiérrez Calderón; Filippo de Marinis; Antonio Passaro; Sang-We Kim; Shirish M Gadgeel; John Xie; Tao Sun; Melissa Martinez; Mariah Ennis; Elizabeth Fennema; Mahesh Daksh; Dawn Millington; Isabelle Leconte; Ryota Iwasawa; Patricia Lorenzini; Mahadi Baig; Sujay Shah; Joshua M Bauml; S Martin Shreeve; Seema Sethi; Roland E Knoblauch; Hidetoshi Hayashi; MARIPOSA Investigators